Search Results | Blood | American Society of Hematology

1-20 of 2657

2 3 4 5

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

DOI: https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

DOI: https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

Jevgenia Zilberman-Rudenko, Hiroshi Deguchi, MD PhD, Mohammed Hayat, Meenal Shukla, PhD, Jennifer Nagrampa Orje, Zihan Guo, Tine Wyseure, PhD, Laurent O Mosnier, Owen J T McCarty, PhD, Zaverio M. Ruggeri, MD, John H. Griffin, PhD

Blood (2019) 134 (Supplement_1): 3632.

DOI: https://doi.org/10.1182/blood-2019-129312

Published: 2019

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

DOI: https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors

Diego A Pereira-Martins, MSc, Juan L Coelho-Silva, BSc, MSc, Isabel Weinhäuser, MSc, Carol Hassibe Thomé, César Alexander Ortiz Rojas, BSc, Luíse A A Simões, BSc, Fabiola Traina, MD PhD, Michael Heuser, MD, Arnold Ganser, MD, Antonio R. Lucena-Araujo, PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1403.

DOI: https://doi.org/10.1182/blood-2019-131542

Published: 2019

Journal Articles

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Aaron D Goldberg, MD PhD, Catherine C. Coombs, MD, Eunice S. Wang, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, MD, Carlos Enrique Vigil, MD, Boo Messahel, MD, Richard M. Stone, MD, Robert H. Collins, MD

Blood (2019) 134 (Supplement_1): 1326.

DOI: https://doi.org/10.1182/blood-2019-130863

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Gary Gordon, MD PhD, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Jason Tache, DO

Blood (2019) 134 (Supplement_1): 1597.

DOI: https://doi.org/10.1182/blood-2019-128503

Published: 2019

Journal Articles

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Alex Vasuthasawat, BS, MS, Reiko E Yamada, Kham R Trinh, Neiki Rokni, Sherie L Morrison, PhD, John M. Timmerman, MD

Blood (2019) 134 (Supplement_1): 1575.

DOI: https://doi.org/10.1182/blood-2019-131890

Published: 2019

Journal Articles

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

Lei Fan, MD PhD, Chao Wang, Zhiqiang Wang, Xian Zhang, Lei Cao, Yi Miao, MD PhD, Xinyi Du, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 5306.

DOI: https://doi.org/10.1182/blood-2019-129469

Published: 2019

Journal Articles

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

Håkan Mellstedt, MD PhD Prof., Amineh Ghaderi, MSc, Johanna Aschan, MSc, Fariba Mozaffari, MSc,PhD, Ali Moshfegh, MSc,PhD, Birgitta Sander, MD PhD Prof., Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Mohammad Hojjat-Farsangi, MSc,PhD

Blood (2019) 134 (Supplement_1): 5312.

DOI: https://doi.org/10.1182/blood-2019-129773

Published: 2019

Journal Articles

A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies

Simon Timothy Abrams, PhD BSc, Ben Morton, MBChB, MD, Yasir Alhamdi, MBChB, PhD, Mohmad Alsabani, Zhenxing Cheng, Steven Lane, PhD, Ingeborg Welters, PhD, Guozheng Wang, MD PhD, Cheng-Hock Toh, MD

Blood (2019) 134 (Supplement_1): 440.

DOI: https://doi.org/10.1182/blood-2019-128493

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

DOI: https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Aishath S Naeem, PhD, Winnie I Nguy, Svitlana Tyekucheva, PhD, Stacey M. Fernandes, BS, Vanessa Rai, BS, Kevin Ebata, PhD, Eliana B. Gomez, PhD, Barb J. Brandhuber, PhD, Stephen M. Rothenberg, MD PhD, Jennifer R Brown, MD PhD

Blood (2019) 134 (Supplement_1): 478.

DOI: https://doi.org/10.1182/blood-2019-124362

Published: 2019

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

DOI: https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Blood (2019) 134 (Supplement_1): 806.

DOI: https://doi.org/10.1182/blood-2019-128930

Published: 2019

Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 866.

DOI: https://doi.org/10.1182/blood-2019-124210

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

DOI: https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Antonia Lopez-Girona, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka, Chin-Chun Lu, Mary Matyskiela, Gody Khambatta, Lilly Wong, Joshua Hansen, Daniel W. Pierce, Brian E. Cathers, James Carmichael

Blood (2019) 134 (Supplement_1): 1812.

DOI: https://doi.org/10.1182/blood-2019-124338

Published: 2019

Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD

Blood (2019) 134 (Supplement_1): 1869.

DOI: https://doi.org/10.1182/blood-2019-121805

Published: 2019

Journal Articles

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Takayuki Sasano, Saki Kushima, Matsushita Yutaka, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD

Blood (2019) 134 (Supplement_1): 1814.

DOI: https://doi.org/10.1182/blood-2019-123619

Published: 2019

2 3 4 5

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only